SCHEMBL16446549

SCHEMBL16446549

Oc1nc(-c2ccc(Cl)s2)nc2c1CCC2

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE4B Q07343 5/20 0.36
HSD17B1 P14061 3/20 0.35
HSD17B2 P37059 2/20 0.35
PDE4D Q08499 4/20 0.34
LMNA P02545 1/20 0.33
MAPT P10636 1/20 0.33
KMT2A Q03164 1/20 0.33
ACHE P22303 5/20 0.33
GRIN1 Q05586 4/20 0.33
GRIN2A Q12879 4/20 0.33
BCHE P06276 4/20 0.33
HTT P42858 1/20 0.33
KDM4E B2RXH2 1/20 0.33
ALDH1A1 P00352 1/20 0.33
HPGD P15428 1/20 0.33
POLB P06746 1/20 0.33
RECQL P46063 1/20 0.33
CASP6 P55212 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15660944 0.85 GRIN1 (0.34) PDE4BPDE4DLMNAMAPTKMT2A
SCHEMBL17476937 0.84 ALDH1A1 (0.33) KMT2AACHEGRIN1GRIN2ABCHE
SCHEMBL15948050 0.82 GRIN1 (0.33) PDE4BPDE4DLMNAMAPTKMT2A
SCHEMBL18833249 0.82 HTT (0.46) LMNAMAPTKMT2AACHEGRIN1
SCHEMBL16179793 0.82 KDM4E (0.36) PDE4BPDE4DLMNAMAPTKMT2A
SCHEMBL15921414 0.82 PDE4B (0.34) PDE4BHSD17B1HSD17B2PDE4DMAPT
SCHEMBL17290212 0.79 PDE4B (0.36) PDE4BHSD17B1HSD17B2PDE4DLMNA
SCHEMBL17290142 0.79 ALDH1A1 (0.35) PDE4BPDE4DLMNAMAPTKMT2A
SCHEMBL17290170 0.77 PDE4B (0.43) PDE4BPDE4DLMNAMAPTKMT2A
SCHEMBL15921129 0.76 PDE4B (0.37) PDE4BHSD17B1HSD17B2PDE4DLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3030565-B1 NOVEL SUBSTITUTED CONDENSED PYRIMIDINE COMPOUNDS GRUENENTHAL GMBH (DE) 2017-07-19 EP disclosed
US-9688683-B2 Substituted condensed pyrimidine compounds Grünenthal GmbH (DE) 2017-06-27 US disclosed
EP-3030565-A1 NOVEL SUBSTITUTED CONDENSED PYRIMIDINE COMPOUNDS Grünenthal GmbH (DE) 2016-06-15 EP disclosed
US-20160152624-A1 NOVEL SUBSTITUTED CONDENSED PYRIMIDINE COMPOUNDS Grünenthal GmbH (DE) 2016-06-02 US disclosed
WO-2015018534-A1 NOVEL SUBSTITUTED CONDENSED PYRIMIDINE COMPOUNDS Grünenthal GmbH (DE) 2015-02-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160152624-A1 NOVEL SUBSTITUTED CONDENSED PYRIMIDINE COMPOUNDS PDE4A, PDE4B, TYMP PDE4B 2/4885HSD17B1 959/4885HSD17B2 815/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.